Aspire Biopharma Holdings, Inc. (ASBPW) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
23150 FASHION DRIVE, SUITE 232 ESTERO, FL 33928 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 250 | 250 | 497 | |||
| Cash and cash equivalent | 250 | 250 | 497 | |||
| Inventory, net of allowances, customer advances and progress billings | ||||||
| Inventory | ||||||
| Other undisclosed current assets | (204) | (169) | 600 | |||
| Total current assets: | 46 | 81 | 1,098 | |||
| Noncurrent Assets | ||||||
| Prepaid expense | 80 | |||||
| Asset, held-in-trust | 6,669 | 19,901 | 299,004 | |||
| Total noncurrent assets: | 6,669 | 19,901 | 299,084 | |||
| TOTAL ASSETS: | 6,714 | 19,982 | 300,182 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 1,031 | 152 | 181 | |||
| Accounts payable | ||||||
| Accrued liabilities | 123 | |||||
| Other undisclosed accounts payable and accrued liabilities | 1,031 | 152 | 58 | |||
| Debt | 466 | |||||
| Derivative instruments and hedges, liabilities | ||||||
| Other liabilities | 359 | 239 | ||||
| Due to related parties | ✕ | ✕ | ✕ | 123 | ||
| Other undisclosed current liabilities | 13,761 | 12 | ||||
| Total current liabilities: | 15,616 | 403 | 303 | |||
| Noncurrent Liabilities | ||||||
| Other undisclosed noncurrent liabilities | 10,813 | |||||
| Total noncurrent liabilities: | 10,813 | |||||
| Total liabilities: | 15,616 | 403 | 11,116 | |||
| Temporary equity, including noncontrolling interest | 6,669 | 19,901 | ||||
| Equity | ||||||
| Equity, attributable to parent, including: | (15,570) | (322) | (9,938) | |||
| Common stock | ||||||
| Additional paid in capital | 8,803 | 10,965 | ||||
| Accumulated deficit | (24,374) | (11,288) | (9,939) | |||
| Other undisclosed equity, attributable to parent | 1 | 1 | 1 | |||
| Other undisclosed equity | 299,004 | |||||
| Total equity: | (15,570) | (322) | 289,066 | |||
| TOTAL LIABILITIES AND EQUITY: | 6,714 | 19,982 | 300,182 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of revenue (Cost of Product and Service Sold) | |||||
| Gross profit: | |||||
| Operating expenses | (3,089) | (1,340) | (976) | ||
| Operating loss: | (3,089) | (1,340) | (976) | ||
| Nonoperating income (expense) | (9,449) | 5,804 | 4,317 | ||
| Investment income, nonoperating | 549 | 5,813 | 4,317 | ||
| Interest and debt expense | (892) | (9) | |||
| Income (loss) from continuing operations before equity method investments, income taxes: | (13,429) | 4,455 | 3,340 | ||
| Other undisclosed income from continuing operations before income taxes | |||||
| Income (loss) from continuing operations: | (13,429) | 4,455 | 3,340 | ||
| Other undisclosed net income | 9 | ||||
| Net income (loss): | (13,429) | 4,464 | 3,340 | ||
| Other undisclosed net income attributable to parent | 892 | ||||
| Net income (loss) attributable to parent: | (12,537) | 4,464 | 3,340 | ||
| Preferred stock dividends and other adjustments | 549 | 5,813 | (33,209) | ||
| Net income (loss) available to common stockholders, diluted: | (11,989) | 10,277 | (29,869) | ||
Comprehensive Income ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
| Net income (loss): | (13,429) | 4,464 | 3,340 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (13,429) | 4,464 | 3,340 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.